Author Archive: George Goodno

George Goodno

George is the Director of State Policy Communications at BIO and enjoys the opportunity to advocate for and educate audiences about the positive societal and economic impact of the bioscience industry. Another great aspect of his job is getting to work with BIO’s broad network of state bioscience associations to help advance legislative and regulatory initiatives that will continue to improve this high-skill, high-wage industry. In his spare time, he enjoys running, skiing, hiking, gardening, and most of all, spending time with his awesome wife and two daughters.

Follow him on Twitter @ggoodno

 

Latest Posts

Universities Express Concerns About Recently Passed House “Innovation Act”

Earlier this month, the House passed the Innovation Act (H.R. 3309), which seeks to address abuses of the U.S. patent litigation system. While the goal is commendable, the bill is overly broad in important respects and if enacted into law would produce unintended and unknowable consequences for innovators who rely on the patent system to fund and protect their inventions. The U.S. Senate is now developing similar legislation, the Patent Transparency and Improvement Act of Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , ,

Kick-Off Planning for San Diego Convention

mayor115x76

The BIO 2014 International Convention in San Diego is just around the corner. With that in mind, we kicked planning efforts into high gear the week before Thanksgiving. The week started with a press conference featuring Interim Mayor Todd Gloria, BIO International Convention President Scott Whitaker, Convention Center President Carol Wallace, and Biocom President and CEO Joe Panetta. After that, productive meetings were held with the convention Steering, Program and Host Committees, as well as Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

NYC Launches $100M Life Science Fund

On Tuesday, Deputy Mayor Robert Steel announced that the city is launching the New York City Emerging Life Science Technology Investment Fund, a $100 million venture fund for life sciences research. New York City will invest $10 million along with $40 million from Eli Lilly, Celgene and GE Ventures, with the remaining $50 million matched by venture capital partnerships. The fund will be used to invest in 15-20 early-stage research and development companies by 2020. Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , ,

Bridging Research to Cures: Summit for R&D Companies

admin-ajax copy

As human and animal health companies struggle to advance medical innovation while managing costs, the outsourcing of research and development functions has become a critical strategy for success. BioResearch Central provides the outsourcing resources needed to accelerate healthcare innovation, to reach patients faster. Born of the legacy of Marion Laboratories and supported by a highly experienced workforce, BioResearch Central companies provide a breadth of services including discovery, toxicology, bioanalytics, clinical trials, regulatory and commercial support. Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , ,

South Carolina Governor Haley at SCBIO Conference

facetoface

BIO’s allied organization in South Carolina will be hosting their third annual conference later this month. SCBIO will be hosting the state’s top chief executive Gov. Nikki Haley as the keynote speaker, along with global biotech financier and analyst G. Steven Burrill. “The Governor played such a critical role in recruiting Nephron and Spirit Pharmaceuticals to the state, her coming signals the significance of this sector, ” said Tom McLean, Chairman of SCBIO. “We also want Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , ,